The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2016 | The importance of individually customized treatment for CLL patients
Davide Rossi, MD, PhD from University of Eastern Piedmont, Vercelli, Italy outlines the novel treatment options for chronic lymphocytic leukemia (CLL) patients. Due to the vast number of these new treatments doctors need to have tools to help them tailor treatments to the patient. Consequently there is a growing need to develop prognostic and predictive factors that may help in the customization of treatment. Recorded at the European Hematology Association (EHA) 2016 Annual Congress in Copenhagen, Denmark.
